[Effect of Regelan (Atromid-S) on serum lipids and platelet aggregation in occlusive arterial disease].
D000924:Anticholesteremic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001162:Arteriosclerosis Obliterans / Q000097:blood* / Q000188:drug therapy; D001792:Blood Platelets / Q000187:drug effects*; D002087:Butyrates / Q000494:pharmacology* / Q000627:therapeutic use; D002784:Cholesterol / Q000097:blood*; D002986:Clinical Trials as Topic; D003374:Coumarins / Q000494:pharmacology; D006801:Humans; D000960:Hypolipidemic Agents / Q000494:pharmacology / Q000627:therapeutic use; D014280:Triglycerides / Q000097:blood*
D000924:Anticholesteremic Agents; D002087:Butyrates; D003374:Coumarins; D000960:Hypolipidemic Agents; D014280:Triglycerides; D002784:Cholesterol
Zur Wirkung von Regelan (Atromid-S) auf Serumlipoide und Plättchenaggregation bei arterieller Verschlusskrankheit.